IP Library Granted Patent US 8,916,171
Granted Patent B2
US 8,916,171 · App. 13/095,227 · Granted Dec 23, 2014

Topical delivery of viscous medications for the treatment of diseases associated with chronic sinusitis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,916,171
App. No.
13/095,227
Granted
Dec 23, 2014
Kind
B2
Abstract

A medication or combination of medications for the treatment of a disease involving the sinuses is incorporated into a sterile medical gel. The viscosity of the gel or the adhesion of the gel to the patient's sinus cavity allows the gel to be maintained in the cavity for a sufficient length of time for treatment of the affected area. This reduces the amount of wasted medication that would otherwise result from other topical methods.

Claims (44)

1. A medicated gel, comprising:

a sterile viscous fluid having a viscosity sufficient to be maintained within a human paranasal sinus cavity after insertion; and

a medication dispersed in the sterile viscous fluid;

wherein the pH of the medicated gel is not adjusted by the addition of any acids, bases, or buffers, and the osmolality of the medicated gel is not adjusted by addition of any salts;

wherein the sterile viscous fluid comprises hydroxyethylcellulose, and the medication comprises tobramycin or mometasone.

2. The medicated gel of claim 1 , wherein the sterile viscous fluid has a viscosity between 2,000 centipoise and 128,000 centipoise at 20° C.

3. The medicated gel of claim 1 , wherein the medication further comprises an antimicrobial medication, an antibiotic medication, an anti-inflammatory medication, an anti-fungal medication, a mucolytic medication, an antihistamine medication, a decongestant medication, a vasoconstrictor medication, an anti-viral medication, a chelating agent medication, or an oncologic medication.

4. The medicated gel of claim 1 , wherein the medication further comprises a micro fine Vitamin D3 suspension.

5. A medical kit, comprising:

a syringe; and

a medicated gel disposed within the syringe;

wherein the medicated gel comprises a sterile viscous fluid having a viscosity sufficient to be maintained within a human paranasal sinus cavity after insertion and a medication dispersed in the sterile viscous fluid, the pH of the medicated gel is not adjusted by the addition of any acids, bases, or buffers, and the osmolality of the medicated gel is not adjusted by addition of any salts; and

wherein the sterile viscous fluid comprises hydroxyethylcellulose, and the medication comprises tobramycin or mometasone.

6. The medical kit of claim 5 , wherein the sterile viscous fluid has a viscosity between 2,000 centipoise and 128,000 centipoise at 20° C.

7. The medical kit of claim 5 , wherein the medication further comprises an antimicrobial medication, an antibiotic medication, an anti-inflammatory medication, an anti-fungal medication, a mucolytic medication, an antihistamine medication, a decongestant medication, a vasoconstrictor medication, an anti-viral medication, a chelating agent medication, or an oncologic medication.

8. The medical kit of claim 5 , wherein the medication further comprises a micro fine Vitamin D3 suspension.

9. A method of preparing a medicated gel, comprising:

dissolving a medication in a solvent;

forming a sterile gel; and

dispersing the dissolved medication in the gel to form the medicated gel;

wherein the medicated gel has a viscosity sufficient to be maintained within a human paranasal sinus cavity after insertion, the pH of the medicated gel is not adjusted by the addition of any acids, bases, or buffers, and the osmolality of the medicated gel is not adjusted by addition of any salts;

wherein the solvent comprises water or propylene glycol, and the medication comprises tobramycin or mometasone.

10. The method of claim 9 , wherein the medication further comprises a micro fine Vitamin D3 suspension.

11. A medicated gel, comprising:

a sterile viscous fluid having a viscosity sufficient to be maintained within a human paranasal sinus cavity after insertion; and

a medication dispersed in the sterile viscous fluid, wherein the sterile viscous fluid has a viscosity between 2,000 centipoise and 128,000 centipoise at 20° C.,

wherein the medication comprises an antimicrobial medication, an antibiotic medication, an anti-inflammatory medication, an anti-fungal medication, a mucolytic medication, an antihistamine medication, a decongestant medication, a vasoconstrictor medication, an anti-viral medication, a chelating agent medication, or an oncologic medication, wherein the sterile viscous fluid comprise hydroxyethylcellulose, and the medication comprises tobramycin or mometasone, and

wherein the medication further comprises a micro fine Vitamin D3 suspension; and

wherein the pH of the medicated gel is not adjusted by the addition of any acids, bases, or buffers, and the osmolality of the medicated gel is not adjusted by addition of any salts.

12. A medicated gel, consisting essentially of:

a sterile viscous fluid having a viscosity sufficient to be maintained within a human paranasal sinus cavity after insertion; and

a medication dispersed in the sterile viscous fluid;

wherein the sterile viscous fluid comprises hydroxyethylcellulose, and the medication comprises tobramycin or mometasone.

13. A medical kit, comprising:

a syringe; and

a medicated gel disposed within the syringe;

wherein the medicated gel consists essentially of a sterile viscous fluid having a viscosity sufficient to be maintained within a human paranasal sinus cavity after insertion and a medication dispersed in the sterile viscous fluid;

wherein the sterile viscous fluid comprise hydroxyethylcellulose, and the medication comprises tobramycin or mometasone.

14. A method of preparing a medicated gel, consisting essentially of:

dissolving a medication in a solvent;

forming a sterile gel; and

dispersing the dissolved medication in the gel to form the medicated gel;

wherein the medicated gel has a viscosity sufficient to be maintained within a human paranasal sinus cavity after insertion;

wherein the solvent comprises water or propylene glycol, and the medication comprises tobramycin or mometasone.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 22, 2014
From: COMERICA BANK, AS AGENT
To: TOPICAL SINUS THERAPEUTICS, INC.
Reel/Frame 032729/0585 →
SECURITY AGREEMENT Recorded Jun 29, 2012
From: SINUTOPIC, INC.
To: COMERICA BANK, AS AGENT, A TEXAS BANKING ASSOCIATION
Reel/Frame 028467/0686 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2011
From: REITZ, RUSSELL; OSBAKKEN, ROBERT SCOTT
To: TOPICAL SINUS THERAPEUTICS, INC.
Reel/Frame 026629/0236 →